Distributor inventory | Tablet
Linagliptin 5 mg + Dapagliflozin 10 mg + Metformin 1000 mg (likely extended-release)
Type 2 diabetes mellitus: to improve glycaemic control in adults when diet and exercise are not enough; used as combination therapy when multiple agents are required.
Linagliptin is a DPP-4 inhibitor that increases incretin hormones, boosting glucose-dependent insulin release and reducing glucagon. Dapagliflozin is an SGLT2 inhibitor that increases urinary glucose excretion. Metformin reduces hepatic glucose production and improves insulin sensitivity.
Oral tablet; take exactly as prescribed by physician. Usually taken once daily with food (especially if metformin/ER) to reduce stomach upset; swallow whole if extended-release—do not crush or chew. Maintain adequate hydration and follow diet/exercise advice.
Common side effects of LINABITE-DM 5/10/1000MG TAB may include:
Prescription-only antidiabetic. Metformin: risk of lactic acidosis—avoid in severe kidney impairment; caution in liver disease, alcohol use, dehydration and severe infection; temporarily stop before iodinated contrast/surgery as advised. Dapagliflozin: may cause dehydration, hypotension, genital mycotic infections, UTIs and rare ketoacidosis (can occur with near-normal glucose); monitor renal function and stop if symptoms of ketoacidosis occur. Linagliptin: rare pancreatitis/serious hypersensitivity; seek care for severe abdominal pain or rash. Not for type 1 diabetes or diabetic ketoacidosis. Monitor blood glucose, HbA1c and kidney function regularly.
